Kairos Pharma Statistics
Total Valuation
Kairos Pharma has a market cap or net worth of $13.54 million. The enterprise value is $11.83 million.
| Market Cap | 13.54M |
| Enterprise Value | 11.83M |
Important Dates
The next estimated earnings date is Friday, May 23, 2025, before market open.
| Earnings Date | May 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kairos Pharma has 16.69 million shares outstanding. The number of shares has increased by 9.38% in one year.
| Current Share Class | 16.69M |
| Shares Outstanding | 16.69M |
| Shares Change (YoY) | +9.38% |
| Shares Change (QoQ) | +22.70% |
| Owned by Insiders (%) | 46.46% |
| Owned by Institutions (%) | 0.21% |
| Float | 7.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.26 |
| P/TBV Ratio | 2.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20
| Current Ratio | 4.20 |
| Quick Ratio | 1.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.40 |
Financial Efficiency
Return on equity (ROE) is -192.96% and return on invested capital (ROIC) is -87.69%.
| Return on Equity (ROE) | -192.96% |
| Return on Assets (ROA) | -43.50% |
| Return on Invested Capital (ROIC) | -87.69% |
| Return on Capital Employed (ROCE) | -49.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$650,750 |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 38.32 |
| Average Volume (20 Days) | 156,304 |
Short Selling Information
The latest short interest is 344,846, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 344,846 |
| Short Previous Month | 6,937 |
| Short % of Shares Out | 2.07% |
| Short % of Float | 4.44% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.34M |
| Pretax Income | -812,000 |
| Net Income | -2.60M |
| EBITDA | -2.18M |
| EBIT | -2.34M |
| Earnings Per Share (EPS) | -$0.23 |
Balance Sheet
The company has $1.27 million in cash and n/a in debt, giving a net cash position of $1.27 million or $0.08 per share.
| Cash & Cash Equivalents | 1.27M |
| Total Debt | n/a |
| Net Cash | 1.27M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 4.78M |
| Book Value Per Share | 0.35 |
| Working Capital | 3.18M |
Cash Flow
| Operating Cash Flow | -3.96M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kairos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.38% |
| Shareholder Yield | -9.38% |
| Earnings Yield | -19.86% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Kairos Pharma is $8.33, which is 927.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.33 |
| Price Target Difference | 927.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |